

## Seeking Novel Disease Models of Macular Degeneration

**Daiichi Sankyo**, a global pharmaceutical company, is seeking **disease models of macular degeneration**-specifically atrophic **age-related macular degeneration (AMD)** and **Stargardt disease**-that have high translational potential for clinical use. To this end, they are seeking disease models that are induced by fundamental pathological mechanisms known in AMD or that have demonstrated responsiveness to existing AMD therapies



### Approaches of Interest:

- **In vitro and in vivo disease models** that are **close to human disease states** in terms of disease state inducers, gene expression, and pathology
- **The model should meet at least two of the following criteria:**
  - It is induced by factors that are strongly associated with AMD
  - It demonstrates concordance with human pathology, such as the development of CNV or localized RPE atrophy
  - It shows responsiveness to agents that have exhibited efficacy signals in AMD clinical trials, including complement inhibitors
- Research to **evaluate the efficacy of drugs** using above AMD and Stargardt disease models

### Out of Scope:

- Models that are not applicable to age-related macular degeneration or Stargardt disease
- *In silico* and AI powered models

### Developmental Stages of Interest:

- Opportunities from basic research to preclinical research are within scope
- Opportunities with **animal models** or **in vitro RPE cell models** are of highest interest



### Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

### Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

## Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Company profiles
-  Biotech assets

## Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **2nd March 2026 - 11:59 pm GMT**

### Have any questions?

Contact our team at [campaigns@inpart.io](mailto:campaigns@inpart.io)